We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+10.91%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$254M
AUM Growth
+$22.2M
Cap. Flow
+$5.01M
Cap. Flow %
1.97%
Top 10 Hldgs %
45.13%
Holding
116
New
12
Increased
26
Reduced
50
Closed
24

Top Buys

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$20.9M
2
BOLD
Boundless Bio
BOLD
+$12.2M
3
ZBH icon
Zimmer Biomet
ZBH
+$3.72M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.08M
5
PGNY icon
Progyny
PGNY
+$2.87M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$3.69M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$3.59M
3
ANNX icon
Annexon
ANNX
+$2.96M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$2.89M
5
VERA icon
Vera Therapeutics
VERA
+$2.82M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
76
DELISTED
Blueprint Medicines
BPMC
$418K 0.16%
4,410
+1,940
+79% +$166K
RVMD icon
77
Revolution Medicines
RVMD
$39.9B
$416K 0.16%
12,910
-800
-6% -$23.7K
RDY icon
78
Dr. Reddy's Laboratories
RDY
$9.87B
$403K 0.16%
27,500
+5,000
+22% +$73K
RCKT icon
79
Rocket Pharmaceuticals
RCKT
$340M
$399K 0.16%
14,810
+2,530
+21% +$71.9K
ALKS icon
80
Alkermes
ALKS
$8.22B
$385K 0.15%
14,230
-1,100
-7% -$31.2K
BNTX icon
81
BioNTech
BNTX
$22.9B
$325K 0.13%
3,525
-200
-5% -$19.2K
EXEL icon
82
Exelixis
EXEL
$13.3B
$312K 0.12%
13,140
-850
-6% -$18.9K
MDGL icon
83
Madrigal Pharmaceuticals
MDGL
$10.8B
$302K 0.12%
1,131
-70
-6% -$16.5K
SRRK icon
84
Scholar Rock
SRRK
$5.67B
$274K 0.11%
+15,400
New +$242K
GPCR icon
85
Structure Therapeutics
GPCR
$3.41B
$256K 0.1%
5,964
+2,564
+75% +$108K
DNLI icon
86
Denali Therapeutics
DNLI
$3.65B
$248K 0.1%
12,081
-800
-6% -$15K
NTLA icon
87
Intellia Therapeutics
NTLA
$1.49B
$242K 0.1%
8,800
-500
-5% -$13.9K
HALO icon
88
Halozyme
HALO
$9.79B
$231K 0.09%
5,680
-350
-6% -$13.1K
ARWR icon
89
Arrowhead Research
ARWR
$11.9B
$220K 0.09%
7,682
-500
-6% -$16K
KYTX icon
90
Kyverna Therapeutics
KYTX
$444M
$174K 0.07%
+7,000
New +$195K
LEGN icon
91
Legend Biotech
LEGN
$3.59B
$168K 0.07%
3,000
– –
ZLAB icon
92
Zai Lab
ZLAB
$2.06B
$32K 0.01%
2,000
-2,000
-50% -$42.1K
ACAD icon
93
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-15,060
Closed -$472K
ALLK
94
DELISTED
Allakos
ALLK
– –
-752,381
Closed -$2.05M
AMLX icon
95
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-84,055
Closed -$1.24M
ANNX icon
96
Annexon
ANNX
$835M
– –
-650,911
Closed -$2.96M
BCAB icon
97
BioAtla
BCAB
$5.46M
– –
-14,121
Closed -$1.74M
CNMD icon
98
CONMED
CNMD
$1.39B
– –
-18,100
Closed -$1.98M
EWTX icon
99
Edgewise Therapeutics
EWTX
$4.13B
– –
-327,801
Closed -$3.59M
FDMT icon
100
4D Molecular Therapeutics
FDMT
$532M
– –
-142,510
Closed -$2.89M
1 2 3
4
5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return
BIS
BG Investment Services Hagatna, Guam $120M AUM 17.44% 1-Year Est. Return

Sectoral Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Sectoral Asset Management held 116 positions worth $254M, up 9.5% from $232M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sectoral Asset Management's Q1 2024 filing shows 12 new, 26 increased, 50 reduced and 24 closed positions. Its largest new stake was Boundless Bio: 855,875 shares worth $12.2M. The largest sale was Amgen, an estimated $3.69M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Sectoral Asset Management's largest Q1 2024 buy was Boundless Bio: 855,875 shares worth $12.2M.
  • Sectoral Asset Management added most to LENZ Therapeutics in Q1 2024, an estimated $20.9M increase.
  • Sectoral Asset Management's biggest Q1 2024 reduction was Amgen, cutting an estimated $3.69M.
  • Sectoral Asset Management fully exited Edgewise Therapeutics in Q1 2024, selling an estimated $3.59M.
  • Sectoral Asset Management's ten largest holdings make up 45% of its $254M portfolio in Q1 2024.
  • Sectoral Asset Management opened 12 new positions and closed 24 in Q1 2024.
  • Sectoral Asset Management's portfolio value rose 9.5% quarter-over-quarter to $254M.

Based on Sectoral Asset Management's 13F filing for Q1 2024, filed 14 May 2024.